Laserfiche WebLink
38 <br />Specialty Pharmacy Discount Guarantee <br />Definition <br />Specialty drug discount level based on actual specialty drug utilization for the specialty drugs dispensed through <br />United's specialty Pharmacy Network <br />Measurement <br />Discount targets for individual drugs dispensed through United's specialty Pharmacy Network. See chart below. <br />Criteria <br />Actual utilization, using Average Wholesale Price (AWP) in dollars, using our data, of specialty drugs through <br />Our specialty Pharmacy Network will be multiplied against the discount targets for the individual drugs to <br />determine the overall discount target dollars. This total will be compared to actual discounts achieved for <br />these drugs during the Guarantee Period. <br />Level <br />Customer Specific <br />Period <br />Annual <br />Payment Period <br />Annual <br />Payment Amount <br />The amount the combined actual specialty drug discounts are less than the sum of the individual specialty <br />drug discount targets as computed above. <br />Conditions <br />• Discounts calculated based on the AWP less the ingredient cost; discount percentages are the discounts <br />divided by the AWP. Discounts for retail generic prescriptions represent the average savings off AWP based on <br />Maximum Allowable Cost (MAC) pricing for MAC generics and percentage discount savings off AWP for non -MAC <br />generics. All other discounts represent the percentage discount savings off of AWP. <br />• Specialty drugs dispensed outside United's specialty Pharmacy Network, drugs for which no AWP measure <br />exists and non -drug items are excluded. <br />• United reserves the right to revise or revoke this guarantee if- a) changes in federal, state or other applicable law <br />or regulation require modifications; b) there are material changes to the AWP as published by the pricing agency <br />that establishes the AWP as used in this guarantee; c) Customer makes benefit changes that impact the guarantee; <br />d) there is a material industry change in pricing methodologies resulting in a new source or benchmark <br />Specialty Drug Category <br />Brand Name <br />Guarantee Pricing <br />a <br />Specialty Drug <br />Brand Name <br />Guarante <br />Pricing <br />(AWP- /o) <br />Category <br />AWP - %o <br />ANEMIA <br />ARANESP <br />13.0% <br />HIV <br />RESCRIPTOR <br />14.3% <br />ANEMIA <br />EPOGEN <br />13.2% <br />HIV <br />RETROVIR <br />13.5% <br />ANEMIA <br />PROCRIT <br />13.6% <br />HIV <br />REYATAZ <br />13.5% <br />ANTIHYPERLIPIDEMI <br />C <br />JUXTAPID <br />14.2% <br />HIV <br />SELZENTRY <br />12.6% <br />ANTIHYPERLIPIDEMI <br />C <br />KYNAMRO <br />11.4% <br />HIV <br />STAVUDINE <br />12.6% <br />ANTIHYPERLIPIDEMI <br />C <br />PRALUENT <br />13.5% <br />HIV <br />STRIBILD <br />13.0% <br />ANTIHYPERLIPIDEMI <br />C <br />REPATHA <br />13.5% <br />HIV <br />SUSTIVA <br />14.2% <br />ANTI - INFECTIVE <br />DARAPRIM <br />12.5% <br />HIV <br />TIVICAY <br />12.5% <br />CARDIOVASCULAR <br />NORTHERA <br />13.5% <br />HIV <br />TRIUMEQ <br />13.5% <br />CNS AGENTS <br />HETLIOZ <br />13.5% <br />HIV <br />TRIZIVIR <br />14.2% <br />CNS AGENTS <br />SABRIL <br />14.3% <br />HIV <br />TRUVADA <br />13.4% <br />CNS AGENTS <br />TETRABENAZINE <br />14.5% <br />HIV <br />TYBOST <br />13.5% <br />CNS AGENTS <br />VECAMYL <br />9.4% <br />HIV <br />VIDEX <br />14.3% <br />CNS AGENTS <br />XENAZINE <br />14.5% <br />HIV <br />VIDEX EC <br />14.3% <br />CNS AGENTS <br />XYREM <br />5.5% <br />HIV <br />VIRACEPT <br />14.2% <br />CYSTIC FIBROSIS <br />BETHKIS <br />13.5% <br />HIV <br />VIRAMUNE <br />14.2% <br />CYSTIC FIBROSIS <br />CAYSTON <br />14.0% <br />HIV <br />VIRAMUNE XR <br />14.2% <br />CYSTIC FIBROSIS <br />KALYDECO <br />11.8% <br />HIV <br />VIREAD <br />14.2% <br />CYSTIC FIBROSIS <br />KITABIS PAK <br />12.1% <br />HIV <br />ZERIT <br />14.3% <br />38 <br />